The GP’s Guide to Migraine: Medication Overuse, CGRP, GLP-1s & Adolescent Prophylaxis

Escalating headache frequency in episodic migraine patients is frequently iatrogenic. When patients take acute painkillers too often, they risk driving central sensitization and entering a cycle of Medication Overuse Headache (MOH) In this clinical deep-dive, we break down the microscopic neuroanatomy of the trigeminovascular system, key diagnostic thresholds, and novel trial evidence to build a targeted 3-step management algorithm for primary care. 🔑 Key Clinical Topics Covered The Iatrogenic Trap & Central Sensitization: How frequent acute medication exposure artificially lowers the brain's baseline pain threshold Quantitative Diagnostic Thresholds for MOH: Overuse is measured by treatment days per month, regardless of daily pill count2 10 days/month for triptans, opioids, or combination analgesics2 15 days/month for simple analgesics (NSAIDs, paracetamol) Trigeminovascular Pathophysiology: Moving past the obsolete "vascular headache" model The role of cortical spreading depression in visual aura3 and Calcitonin Gene-Related Peptide (CGRP) release in neurogenic inflammation and trigeminal nociception Breakthrough Trial Data & Targeted Therapies:GLP-1 Agonists (Liraglutide): Substantially reduce monthly migraine days independently of weight loss, pointing to direct inflammatory and CGRP-modulating mechanisms Comorbid Depression (The UNITE Study): Oral CGRP antagonists concurrently reduce monthly headache days and Hamilton Depression (HAM-D) scores in patients with chronic migraine and major depressive disorder Adolescent Prophylaxis via Glutamate Blockade: Repurposing memantine (NMDA receptor antagonist) blocks the brain's "glutamate gas pedal," reducing average adolescent headache days from 22 down to 15 days/month without sedation Diagnostic Precision (NDPH vs. Migraine): CGRP inhibitors show an 86% response rate in non-daily chronic migraine compared to only 23% in New Daily Persistent Headache (NDPH) Lactation Safety: Phase 1 data demonstrating negligible excretion of ubrogepant into breast milk (0.02 mg following a 100 mg dose) ⏱️ Chapter Timestamps 0:00 – The Iatrogenic Cycle: Recognizing Medication Overuse Headache 1:45 – Trigeminovascular System & CGRP Neurochemistry 3:30 – Diagnostic Thresholds: Treatment Days vs. Pill Quantity 5:15 – GLP-1s in Migraine: Weight-Independent Inflammatory Modulation 7:00 – Treating Comorbid Depression & Migraine (UNITE Trial) 8:45 – Non-Sedating Adolescent Prophylaxis: Memantine & Glutamate 10:15 – CGRP Efficacy: Chronic Migraine vs. NDPH 11:30 – Postpartum Safety & Lactation Data1 2:45 – The 3-Step Primary Care Algorithm #Migraine #Neurology #MedicationOveruseHeadache #CGRP #PrimaryCare #MedicalEducation Disclaimer: This video is intended for medical education and healthcare professionals. It does not constitute personal medical advice. Patients should consult their clinician before making changes to any treatment regimen.